ImmuCell Corporation (ICCC)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA Summary
ImmuCell: First Defense With Better Execution
ImmuCell's main value driver is First Defense. In my view, this is their core franchise and has real commercial momentum across year-round dairy customers. They've also shown improving manufacturing yields and redirected Re-Tain assets towards First Defense's production capacity. My main concern with ICCC is that it's heavily reliant on two main distributors, as well as concentrated on First Defense as its main product.
ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand
ICCC reports an 11.5% rise in preliminary Q2 sales, driven by robust U.S. demand and improved product availability, extending the momentum from its strong Q1 performance.
ICCC's Valuation Remains Premium: Is it Worth Overpaying for?
ImmuCell's premium valuation is backed by rising output, First Defense share gains and a sizable untapped calf-health market opportunity.
ImmuCell Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 250 | $1,537.5 | $2,802.5 | $1,265 | 82.28% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 5 | $50 | $55.35 | $5.35 | 10.7% |
 Steadtrust LLC Steadtrust LLC | 45,370 | $281,055.72 | $508,597.7 | $227,541.98 | 80.96% |
ImmuCell Corporation (ICCC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ImmuCell Corporation ever had a stock split?
ImmuCell Corporation Profile
| Biotechnology Industry | Healthcare Sector | F. Olivier Te Boekhorst CEO | NASDAQ (CM) Exchange | 452525306 CUSIP |
| US Country | 73 Employees | - Last Dividend | 25 Jul 1990 Last Split | 30 Apr 1987 IPO Date |
Overview
ImmuCell Corporation is a distinguished entity in the animal health sector, specifically dedicated to advancing the welfare and efficiency of dairy and beef cattle both domestically in the United States and on an international scale. With its inception in 1982, the company has carved out a significant niche in developing, manufacturing, and selling innovative products aimed at improving cattle health. ImmuCell operates through two primary segments: Scours and Mastitis, showcasing its specialized focus on combating significant health challenges in cattle. The company’s headquarters are located in Portland, Maine, reflecting its longstanding commitment and contribution to the animal health industry.
Products and Services
- First Defense
- Tri-Shield First Defense
- California Mastitis Test
- Dual-Force First Defense
- Re-Tain Drug Product
An oral preventative product designed for calves, First Defense addresses scours by defending against pathogens like E. coli, coronavirus, and rotavirus. Its formulation and ease of administration make it a critical tool in early calf health management.
This is an enhancement of the original First Defense, offering a passive antibody product specifically targeting the treatment of E. coli, coronavirus, and rotavirus within the calf population. It represents a step forward in preventing common but severe illnesses in calves.
A quick and effective on-farm diagnostic tool, the California Mastitis Test assists farmers in detecting somatic cell counts in milk, which is vital for identifying mastitis. The test helps in pinpointing which quarter of the udder is afflicted, facilitating timely and appropriate treatment.
This product offers a bivalent gel tube formulation, expanding the protective capabilities against pathogens that calves are exposed to, further illustrating ImmuCell’s commitment to innovative and practical solutions in animal health.
Currently under development, Re-Tain signifies ImmuCell's venture into intramammary treatments. This Nisin-based product aims to treat subclinical mastitis in lactating dairy cows, potentially revolutionizing mastitis management with an emphasis on subclinical conditions.
